OPKO Health, Inc. Earnings Recaps
Q3 2026
Nov 6, 2026
OPKO shares slipped 1.1% after earnings, a roughly flat reaction. The call highlighted pipeline progress and the planned LabCorp exit, but provided no financial outlook figures in the transcript excerpt, leaving the near-term performance picture unclear.
Key takeaways
- OPKO said the LabCorp transaction, once closed, will complete its exit from clinical laboratory services and refocus the company on biotech and global products.
- ModeX’s MDX-2001 Phase I study had enrolled 41 patients as of September 30; subcutaneous dosing is expected to begin in late 2026 or early 2027.
- MDX-2003 continued dose escalation, with six sites active as of September 30 and two more being added; eight European sites are planned by early 2027.
- MDX-2004 had enrolled 16 patients and advanced to its fourth dose cohort; subcutaneous studies are expected to begin in early 2027.
- OPKO repurchased over 7 million shares during the quarter, with more than $80 million remaining under its $220 million authorization.
Q2 2026
Jul 30, 2026
OPKO Health's shares surged 35.2% following Q2 2026 results, driven primarily by clear progress across multiple clinical pipeline programs and sustained financial strength, which appear to have exceeded investor expectations.
Key takeaways
- ModeX advanced five clinical trial programs spanning oncology, immunology, and vaccines, with an anticipated sixth in vivo CAR-T asset to enter clinical trials by end of 2026 or early 2027.
- Merck-funded MDX2201 vaccine against Epstein-Barr virus is completing Phase I data analysis, with Phase II study design expected by year-end.
- Early clinical milestones for MDX2001, MDX2003, MDX2004, and MDX2301 highlight diversified pipeline activity, including ongoing Phase I trials and planned data presentations in late 2026 and 2027.
- Solid balance sheet and operating efficiency improvements sustained a strong cash position while enabling continued R&D funding and capital return via stock repurchases.
- Collaborations with Regeneron and BARDA bolster pipeline breadth, supporting late-stage immuno-oncology and infectious disease programs underpinned by multi-specific antibody platform technology.
Q3 2025
Oct 30, 2025
OPKO Health's Q3 2025 results showcased strategic progress, highlighted by the successful sale of its oncology division and a focus on core clinical operations, driving a commitment to shareholder value.
Key takeaways
- Completed the sale of BioReference Health's oncology division for $192.5 million plus an additional $32.5 million in performance-based earn-out.
- Achieved a 5.3% increase in testing volume at BioReference, with a 20% rise in adoption of the 4Kscore test for prostate cancer.
- Repurchased $25.1 million in stock during 2025 to enhance shareholder returns, with $126 million remaining under the repurchase program.
- Advanced pipeline with four therapeutics in clinical development, including promising candidates in the immuno-oncology space and a COVID-19 antibody initiative.
- Focused on operational efficiencies and growth through new customer segments and revenue streams, maintaining a streamlined workforce at BioReference.